Table 1 Demographics of acute graph-versus-host disease patients receiving mesenchymal stromal cell therapy

Total number of patients

8

8

Age at HSCT (years): median (min–max)

58.4 (34.0–64.9)

54.3 (13.5–65.8)

0.96^a

Female sex: N (%)

4 (50)

2 (25)

0.61^b

 Myeloid neoplasm

4 (50)

7 (87.5)

0.35^b

 Lymphoid neoplasm

2 (25)

1 (12.5)

 Plasma cell dyscrasia

1 (12.5)

0 (0)

 Prostate cancer

1 (12.5)

0 (0)

 HLA-identical sibling

5 (62.5)

5 (62.5)

1^b

 Matched unrelated donor

3 (37.5)

3 (37.5)

 Standard

5 (62.5)

6 (75)

1^b

 Reduced intensity (RIC)

3 (37.5)

2 (25)

 Time from HSCT or DLI to aGVHD

32.5 (13–107)

35.5 (11–169)

0.96a

 Time from aGVHD diagnosis to steroid treatment

1.5 (0–7)

1 (0–7)

0.91^a

 Time from steroid treatment to MSC treatment

8 (3–44)

15 (4–55)

0.17^a

 Time from steroid treatment to biopsy^#

2 (0–13)

6 (1–29)

0.18^a

 Biopsy before initiation of steroid treatment (N)

1

0

1^b

 Time from biopsy to MSC treatment

5.5 (2–37)

9.5 (3–26)

0.34^a

 Grades 0–I

0 (0)

0 (0)

NA

 Grade II

0 (0)

0 (0)

 Grades III–IV

8 (100)

8 (100)

 Grades 0–I

0 (0)

3 (37.5)

0.077^b

 Grade II

0 (0)

1 (12.5)

 Grades III–IV

8 (100)

4 (50)

 CMV colitis

2 (25)

3 (37.5)

1^b

 CMV viremia (> 1000 copies/ml)

2 (25)

4 (50)

0.61^b

 Total leukocytes (× 10⁹)/L)

11.26 (± 1.86)

9.86 (± 8.28)

1^a

 Neutrophils (× 10⁹/L)

8.98 (± 1.81)

7.79 (± 6.54)

1^a

 Eosinophils (× 10⁹/L)

0.04 (± 0.07)

0.05 (± 0.09)

0.82^a

 Basophils (× 10⁹/L)

0.01 (± 0.01)

0.05 (± 0.09)

0.65^a

 Lymphocytes (× 10⁹/L)

0.90 (± 0.66)

0.63 (± 0.49)

0.60^a

 Monocytes (× 10⁹/L)

1.00 (± 0.70)

1.19 (± 1.47)

0.84^a